CRYPTOCOCCAL SCREENING

A New Strategy for Saving Lives among People with HIV/AIDS

National Center for Emerging and Zoonotic Infectious Diseases Division of Foodborne, Waterborne, and Environmental Diseases



Cryptococcal Meningitis: Reducing Deaths by Screening for Infection

Tom Chiller, MD MPHTM

Mycotic Diseases Branch U.S. Centers for Disease Control and Prevention


> Fifth Annual CUGH conference May 12, 2014



National Center for Emerging and Zoonotic Infectious Diseases

Cryptococcus Neoformans

- Fungus found in soil, trees, bird feces
- Incubation period unknown, can be dormant for many years
- Reactivation in immunosuppressed (HIV/AIDS, especially CD4<100)</p>
- No person-to-person transmission
- Usually presents as meningitis
 - Requires hospitalization and treatment with intravenous (IV) amphotericin B



India Ink microscopy of *Cryptococcus*


Cryptococcal Meningitis (CM)

- 1 million new cases per year globally
 - Resulting in 625,000 deaths
- Most common cause of adult meningitis in sub-Saharan Africa
- High mortality (>50%) due to:
 - Late presentation to care
 - Limited access to effective medications
 - Limited access to sensitive and specific diagnostics

Frequent cause of IRIS (20-30% early mortality after ART)


Cryptococcal Meningitis Survival

- If untreated, casefatality is 100%
- In sub-Saharan Africa, mortality likely 50-70%



Kambugu et al, CID 2008

Causes of death in sub-Saharan Africa (excluding HIV/AIDS)



Disease progression in HIV-infected person

Latent infection	Subclinical infection	Meningitis
Disease confined to the lungs	Antigen is detectable in the blood; no symptoms of CM	Days to months later Dissemination to the brain

How is Cryptococcus currently detected?

	MICROSCOPY	CULTURE	ANTIGEN DETECTION
Methods	India Ink staining of the fungi	Bird seed agar	Detects the fungal polysaccharide capsule
Test characteristics	Rapid diagnosis; 30-80% Sensitivity	Confirmatory test; Less sensitive than other methods	90-100% sensitivity; Excellent specificity
Specimen used	CSF	CSF, blood, any sterile fluid	CSF, blood
Picture			

A novel POCT antigen test is available


The new dipstick test (Lateral Flow Assay, or LFA) is:

- Simple and quick Results in 10 minutes
- Accurate Highly sensitive, accurate (>95%)
- Affordable

\$2/test

Easy to use

Little lab infrastructure and no cold chain required



*FDA-approved in serum and cerebrospinal fluid (CSF).

LFA for resource-limited settings

- No cold chain or laboratory infrastructure required
 Available in Africa at cost from manufacturer
 - Available from manufacturer, SCMS, local distributors
- Detects both subclinical disease and meningitis
- Can be used in dedicated laboratories as well as in clinics as a point of care test


Useful in facilities utilizing point of care CD4 testing

CrAg LFA is the ONLY Point-of-Care Diagnostic




"Screen and Treat" strategy

Screen a subset of HIV infected patients with a CrAg test and treat only those with a positive test
 Detect early cryptococcal disease and prevent progression to meningitis through early treatment




Survival of People with Asymptomatic Cryptococcal Antigenemia starting HIV




INSTITUTI



Meva et al. CID 2010




Cryptococcal Screening Algorithm for HIV+ Patients-- South Africa



- + A lumbar puncture may considered in asymptomatic patients. Pregnant women, children, and those with liver failure may require special attention.
- * Initiate ART if not already started

Some Countries are Screening



South Africa

CrAg screening included in National Strategic Plan for HIV

- Persons with CD4<100
- Phased national implementation
- Phase 1: Sept 2012 present
 - Screening in two provinces
- Phase 2
 - National roll-out
- 19,000 people screened, 5%
 CrAg-positivity



Mozambique

- Screening among those with CD4<100</p>
- Pilot screening in 3 provinces
 - 3 facilities in each province
- Screening in different lab settings
 - Pima POC CD4
 - FACS on-site
 - Referral laboratory reflex testing
- Phased national implementation
 - Mozambique Ministry of Health with PEPFAR support



Key elements for successful implementation

- Integrating screening into national guidelines
- Engaging key strategic partners
 - ASLM support lab capacity building and accreditation
 - PEPFAR funding in-country cryptococcal activities
 - MSF/CHAI antifungal and diagnostics access advocacy
- Building laboratory capacity
 - Laboratory training, test validation, LFA EQA
 - Diagnostic test procurement, distribution

Improving access to essential antifungal medicines

Amphotericin B, Fluconazole, Flucytosine

Previous Training - Haiti

1 day workshop
 POC

 Crypto
 Syphillis
 Malaria



ASLM RDT/POC Roadshow

Combination Training on RDTs



HIV/Syphilis Duo

Malaria

CrAg LFA

Coming Soon: African Society for Laboratory Medicine Rapid Diagnostic Test (RDT) Training Course

Why Rapid Diagnostic Tests?

Rapid Diagnostic Tests (RDTs) to detect HIV and other diseases are being used more frequently because they are simple to use and can give results faster than traditional diagnostic methods. RDTs are ideal for HIV screening in Africa because many laboratories do not have access to viral load testing, which can be expensive and resource-intensive. In addition, RDTs can quickly detect other infections common among people living with HIV/AIDS, such as syphilis, malaria, and cryptococcal meningitis (a fungal infection).



HIV/AIDS

- 35 million people currently living with HIV/AIDS globally
- · Less than half know their status



Cryptococcal disease

- Worldwide over 500,000 people die each year from cryptococcal meningitis
- Screening and preemptive treatment is both cost- and life-



- Misdiagnosis and treatment occurs in up to 90% of febrile patients in some settings
- RDTs provide quick and accurate diagnoses to guide treatment

Syphilis

- Responsible for over 500,000 babies born with birth defects
- Easily treatable in childbearing
 age women if detected early



ASLM plans to offer training on HIV/syphilis, malaria, and cryptococcal disease RDTs in the summer of 2015.

Clinical staff training includes:

- Use of evidence-based treatment and decisionmaking algorithms
- Didactic and active role play-based learning
- Case-studies based on real-world examples

Learning objectives:


- To demonstrate competency in clinical diagnosis, treatment, and case management
- To obtain an understanding of epidemiological aspects of priority diseases
- To apply programmatic concepts for screening strategies to a local context

Laboratory staff training including:

- Hands-on experience performing and interpreting key RDTs
- Development of standard algorithms for determining and reporting low-positive test lines
- Enhanced skill-building in data recording and database management practices

Learning objectives:

- To gain a better understanding of basic clinical aspects of each disease
- To streamline laboratory workflow
- To utilize proficiency testing and quality assurance





Advocacy - CryptoMAG

International, multi-organizational coalition

- Academic, International, governmental and non-governmental
 - CHAI, PEPFAR, LSHTM, MSF, NICD, WHO

Priorities

- Improve access to accurate diagnostic tests
- Improve access to essential antifungal medicines
- Disseminate clinical practices and guidelines

Accomplishments to-date

- Addition of Flucytosine and Amphotericin B on WHO core essential medicines list (EML)
- High profile publications on toxicity and access issues
- Satellite sessions at international conferences (ASLM, ICASA)













www.preventcrypto.org

Conclusion


- Cryptococcal infection is an important public health problem among people living with HIV
- Antigen tests can detect cryptococcal infection early before it develops into meningitis
- The LFA can be used in both laboratory and as a POCT
- Advocacy for diagnostics and essential medicines must accompany screening programs

Thank you!

HIV and Brain Infection: Testing Saves Lives!

What is the infection?

Some people with HIV can get a brain infection called *Cryptococcus* or "Crypto." If it is not treated, you could get very sick. Crypto is caused by a small germ.



How is it spread?

This germ lives in the soil but is too small to see. It can enter our bodies through the air we breathe. Most people are strong enough not to get sick. In an HIV+ person it may start growing and can spread to the brain.

The germ CANNOT spread from person to person!



What can I do?

Even if you do not feel sick now, you might already have this infection. Your doctor will test you as part of your regular visit. If you have the Crypto germ, you will need to take medicine so that you do not get sick later.





National Center for Emerging and Zoonotic Infectious Diseases